Institut Català de la Salut
[Alves J] Infectious Diseases Department, Hospital de Braga, Braga, Portugal. [Abreu B] Pharmaceuticals Department, Hospital de Braga, Braga, Portugal. [Palma P] Infectious Diseases Department, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal. [Alp E] Infectious Diseases and Clinical Microbiology Department, Ankara Yıldırım Beyazıt University, Ankara, Turkey. [Vieceli T] Infectious Diseases Department, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. [Rello J] Grup de Recerca Clínica/Innovació en la Pneumònia i Sèpsia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. FOREVA Research Pôle, Centre Hôpitalaire Universitaire de Nîmes, Nîmes, France
Vall d'Hebron Barcelona Hospital Campus
2023-06-15T05:53:30Z
2023-06-15T05:53:30Z
2023-05
Prescription optimization; Critically ill patients; Appropriate antibiotic
Prescripció antimicrobiana; Pacients crítics; Antibiòtic adequat
Prescripción antimicrobiana; Pacientes críticos; Antibiótico adecuado
The emergence of antibiotic resistance poses a global health threat. High-risk patients such as those with neutropenia are particularly vulnerable to opportunistic infections, sepsis, and multidrug-resistant infections, and clinical outcomes remain the primary concern. Antimicrobial stewardship (AMS) programs should mainly focus on optimizing antibiotic use, decreasing adverse effects, and improving patient outcomes. There is a limited number of published studies assessing the impact of AMS programs on patients with neutropenia, where early appropriate antibiotic choice can be the difference between life and death. This narrative review updates the current advances in strategies of AMS for bacterial infections among high-risk patients with neutropenia. Diagnosis, drug, dose, duration, and de-escalation (5D) are the core variables among AMS strategies. Altered volumes of distribution can make standard dose regimens inadequate, and developing skills towards a personalized approach represents a major advance in therapy. Intensivists should partner antibiotic stewardship programs to improve patient care. Assembling multidisciplinary teams with trained and dedicated professionals for AMS is a priority.
Artículo
Versión publicada
Inglés
Neutropènia - Tractament; Medicaments antiinfecciosos - Ús terapèutic; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropenia; Other subheadings::Other subheadings::Other subheadings::/drug therapy; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos leucocitarios::leucopenia::agranulocitosis::neutropenia; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
MDPI
Microorganisms;11(5)
https://doi.org/10.3390/microorganisms11051127
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]